Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of AZD7442 (Evusheld) in Healthy Japanese Participants
NCT04896541Phase 1Completed
- Sponsor
- AstraZeneca
- Start
- Mar 2021
- Primary completion
- Jun 2022
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in coronavirus disease 2019 (COVID-19) comparing AZD7442 with Placebo (2 arms). Primary endpoints: Adverse event and serious adverse event at Day 361, Pharmacokinetics - Serum Concentration at Day 361 and 7 more. Started Mar 2021; status: completed.
02
Drugs
tixagevimab + cilgavimab
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04896541.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04896541.